Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

H1N1 Influenza: Information For Donors
No Additional Risk

Changing Paradigms In Hereditary Angioedema: A Focus On Timely Diagnosis And New Therapies
Hereditary angioedema (HAE) is an autosomal dominant disease affecting approximately 10,000 people in the United States. HAE causes recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. While chronic therapy with attenuated androgens or plasmin inhibitors has been the mainstay of HAE therapy, many new therapies for prophylaxis and acute treatment are on the horizon. It is important for physicians to understand the signs and symptoms of patients who present with HAE and to be familiar with the conventional and emerging therapies available to treat them.
News of the day
Palliative Care Research To Benefit From $1.5 Million Award
The American Cancer Society and the National Palliative Care Research Center (NPCRC) are awarding $1.5 million in research grants to researchers at eleven institutions for studies aimed at reducing suffering for seriously ill patients and their family caregivers. The studies will be conducted over the next two years. The NPCRC, in collaboration with the American Cancer Society, has directed over $5 million towards supporting 38 palliative care research projects since starting this initiative three years ago.
Endocrinology

Hormone Therapy Use Associated With Increased Risk Of Ovarian Cancer

Compared with women who have never taken hormone therapy, those who currently take it or who have taken it in the past are at increased risk of ovarian cancer, regardless of the duration of use, the formulation, estrogen dose, regimen or route of administration, according to a study in the July 15 issue of JAMA. Primary prevention of ovarian cancer is challenging because little is known about its cause. Studies have suggested an increased risk of ovarian cancer among women taking postmenopausal hormone therapy (HT), according to background information in the article. Data have been limited on the differing effects of formulations, regimens and routes of administration. Lina Steinrud MÃñrch, M.Sc., of Rigshospitalet, Copenhagen University, Denmark, and colleagues conducted a study to examine the risk of ovarian cancer associated with hormone therapy use. The study included all Danish women age 50 through 79 years from 1995 through 2005 through linkage to Danish national registers. Prescription data from the National Register of Medicinal Product Statistics provided individually updated information on HT use. The National Cancer Register and Pathology Register provided ovarian cancer incidence data. The analysis included a total of 909,946 women without hormone-sensitive cancer or who had not had both ovaries removed. At the end of follow-up, 63 percent of the women had not been taking HT, 22 percent were previous users of hormones, and 9 percent current users of hormones. Among the current users, 46 percent had used hormones for more than 7 years. During an average of 8 years of follow-up, 3,068 ovarian cancers were detected . Of these, 2,681 were epithelial tumors (a type of ovarian cancer). Compared with never users, current users of HT had an overall 38 percent increased risk of ovarian cancer. When restricting the analyses to epithelial ovarian cancer, the relative risk among current HT users was 44 percent higher, with previous HT users having a 15 percent increased risk compared with women who had never used HT. The risk for ovarian cancer and epithelial ovarian cancer did not increase significantly with increasing durations of HT. The risk of ovarian cancer declined with longer time since last HT use. The risk of ovarian cancer did not differ significantly by formulation, regimen, type of progestin or route of administration. The absolute risk indicated approximately 1 extra ovarian cancer for roughly 8,300 women taking hormone therapy each year. "If this association is causal, use of hormones has resulted in roughly 140 extra cases of ovarian cancer in Denmark over the mean follow-up of 8 years, i.e., 5 percent of the ovarian cancers in this study. Even though this share seems low, ovarian cancer remains highly fatal, so accordingly this risk warrants consideration when deciding whether to use HT," the authors write. JAMA 2009;302[3]:298-305. Journal of the American Medical Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009